A large study that retrospectively analyzed the visual outcomes and rate of development of neovascular age-related macular ...

But until recently, we haven’t had any therapeutics to target the root cause of geographic atrophy, an advanced form of dry AMD. Pegcetacoplan (Syfovre) is the first FDA-approved drug to slow ...

Geographic atrophy is a subtype of advanced age-related macular degeneration (AMD). It causes blind spots in the center of vision and a permanent loss of visual sharpness. AMD progresses through ...

Geographic atrophy (GA) can be visually confusing. People often tell me that one minute they see something, and the next minute they don’t. For example, the word you’re reading might be “she ...

Certain imaging biomarkers and demographic factors are associated with geographic atrophy growth rate and may guide the selection of patients for the use of newer therapeutics. Share on Facebook.

In this CE activity, experts in the field will assess how advances in imaging and new therapies for the management of geographic atrophy secondary to age-related macular degeneration can be ...

Pegcetacoplan (Syfovre) is now approved in Australia for treating geographic atrophy (GA) secondary to age-related macular ...

The phase 1b trial will enrol patients with geographic atrophy secondary to age-related macular degeneration (AMD), a leading cause of blindness. While there are multiple therapies available for ...